Kezar Life Sciences Stock (NASDAQ:KZR)
Previous Close
$6.64
52W Range
$5.20 - $11.40
50D Avg
$7.27
200D Avg
$7.13
Market Cap
$49.76M
Avg Vol (3M)
$82.91K
Beta
0.22
Div Yield
-
KZR Company Profile
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
KZR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| BOLT | Bolt Biotherapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. |
| IPSC | Century Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| SRZN | Surrozen, Inc. |
| DSGN | Design Therapeutics, Inc. |
| NKTX | Nkarta, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| IKNA | Ikena Oncology, Inc. |
| KROS | Keros Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| STTK | Shattuck Labs, Inc. |